Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007144316 - VACCINE

Publication Number WO/2007/144316
Publication Date 21.12.2007
International Application No. PCT/EP2007/055676
International Filing Date 08.06.2007
Chapter 2 Demand Filed 06.06.2008
IPC
A61K 39/095 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
095Neisseria
C07H 13/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
13Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
CPC
A61K 2039/55505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55505Inorganic adjuvants
A61K 2039/55555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
A61K 2039/55561
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55561CpG containing adjuvants; Oligonucleotide containing adjuvants
A61K 2039/6018
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
60characteristics by the carrier linked to the antigen
6018Lipids, e.g. in lipopeptides
A61K 2039/6031
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
60characteristics by the carrier linked to the antigen
6031Proteins
A61K 2039/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
70Multivalent vaccine
Applicants
  • GLAXOSMITHKLINE BIOLOGICALS SA [BE]/[BE] (AllExceptUS)
  • DEVOS, Nathalie [BE]/[BE] (UsOnly)
  • FERON, Christiane [BE]/[BE] (UsOnly)
  • POOLMAN, Jan [NL]/[BE] (UsOnly)
  • WEYNANTS, Vincent [BE]/[BE] (UsOnly)
Inventors
  • DEVOS, Nathalie
  • FERON, Christiane
  • POOLMAN, Jan
  • WEYNANTS, Vincent
Agents
  • LUBIENSKI, Michael John
Priority Data
60/804,47512.06.2006US
60/804,48912.06.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) VACCINE
(FR) VACCIN
Abstract
(EN)
The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer- membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer- membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects.
(FR)
La présente invention concerne le domaine de compositions vaccinales anti-neisseria, leur fabrication et leur utilisation en médecine. Plus particulièrement, elle concerne des procédures pour fabriquer de nouvelles souches de méningocoques modifiées qui sont plus appropriées pour la production de vaccins à vésicule de membrane externe (ou pustule) anti-neisseria, en particulier anti-méningocoques. L'invention concerne également des procédures et des vaccins avantageux basés sur l'utilisation d'une nouvelle sous-unité LOS ou de vaccins à vésicule de membrane externe de méningocoques (ou pustule) qui ont été rendus plus sûrs et plus efficaces pour une utilisation chez des sujets humains.
Latest bibliographic data on file with the International Bureau